

Legal Disclaimer

The information provided herein (the " is not intended to provide financial, tax, legal or accounting advice The contents hereof do not constitute an offer to sell or a solicitation of an offer to buy securities of Safe Supply Streaming Co Ltd (the "or represent an intention to induce any person to make an investment in the Company or to assist any person in the making of an investment decision Information provided in this presentation material (the " or on any website of the Company where this Presentation may appear or be accessed is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States of America in which such offer, solicitation or sale would be unlawful This Presentation includes market share, industry and other statistical information that the Company has obtained from independent industry publications, government publications, market research reports and other published independent sources Such publications and reports generally state that the information contained therein has been obtained from sources believed to be reliable Although the Company believes these publications and reports to be reliable, it has not independently verified any of the data or other statistical information contained therein, nor has it ascertained or validated the underlying economic or other assumptions relied upon by these sources The Company has no intention and undertakes no obligation to update or revise any such information or data, whether as a result of new information, future events or otherwise, except as, and to the extent required by applicable securities laws Any copying, reproduction, republishing, translation, transmission, modification, distribution or other exploitation of the Presentation, or any elements thereof, without the prior written consent of the Company is strictly prohibited


Forward looking information

This Presentation contains "forward looking statements" and "forward looking information" ("forward looking information") within the meaning of applicable securities legislation Forward looking information are generally, but not always identified by the words such as ""may", "would", "could", "will", "likely", "except", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook"," and other similar expressions In addition, the Company's assessment of, and targets for, (the industry, including, the potential opportunities and challenges in the current industry environment and other industry statistics (matters pertaining to the Company, including its strategy, completed, anticipated and potential transactions and the characteristics thereof, future acquisition opportunities and joint ventures, and its pro forma capitalization following the completion of the Company's current investment opportunities (matters pertaining to the Company's current investment opportunities, including the amount and use of proceeds thereof and the anticipated timing to complete and close the Company's current investment opportunities (financial modeling matters and (management's estimated timelines, are all specifically considered

forward looking information Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward looking information in this Presentation, and, accordingly, investors should not place undue reliance on any such forward looking information Forward looking information involves significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward looking information and accordingly, should not be read as guarantees of future performance or results Forward looking information involves risks and uncertainties including, but not limited to, the Company's anticipated business strategies, anticipated trends in the Company's business and anticipated market share, that could cause actual results or events to differ materially from those expressed or implied by the forward looking information, general business, economic and competitive uncertainties, regulatory risks, the economic and industry environment, business and operations of the Company and its investees Due to the nature of the Company's business, the legal and economic climate in which it operates and its present stage and proposed operations, the Company is subject to other significant risks The Company's future development and actual operating results may be very different from those expected as at the date of this Presentation and are dependent in part on the development and actual operating results of the entities it invests in Readers should carefully consider all such risks, which include, but are not limited to, the Company's (and the Company's investee entities, as applicable), limited operating history, no liquid and speculative nature of any investment in the Company, the requirement for additional funding, conflicts of interest, changes in law or the non occurrence of any anticipated changes in law, the receipt of and compliance with any required licenses, permits, authorizations for the business of the Company or its investees, reliance on third parties, compliance with applicable laws, risks related to the potential denial of banking services due to the industry in which the Company operates, acceptance by the general public and legislators, risks related to access to the denial of insurance coverage or obtaining insurance coverage at reasonable rates Any forward looking statements speak only as of the date on which such statement is made and the Company disclaims any intention or obligation to update or revise any forward looking information as a result of new information, future events or otherwise, unless required by applicable law New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward looking statements Forward looking information contained in this Presentation is based on the Company's current estimates, expectations and projections, which the Company believes are reasonable as of the current date The Company can give no assurance that these estimates, expectations and projections will prove to have been correct Historical statements should not be taken as a representation that such trends will be replicated in the future No statement in this Presentation is intended to be nor may be construed as a profit forecast











Our mission is simple:

to save lives, build a better world and help bring a responsible end to the drug war.

Our Thesis

——→ The War on Drugs is coming to an end.

It has to. Just look at the numbers.

COST OF THE DRUG WAR:

\$1 trillion dollars+ **EFFECT:**

Cannabis, Psychedelics and Cocaine Use is at

all-time highs.

OVERDOSES:

108K

opioid related deaths in 2021 in the US alone



The Third Wave of Reform

It started with cannabis, then psychedelics.

Now the third wave of drug reform is here.

2019

Portugal decriminalized all drugs in 2001.

2001

Oregon, Colorado has decriminalized all drugs. British Columbia has decriminalized all drugs and is taking proactive measures, including the first prescribed safer supply program.

2

Experts around the world, including members of the UN and the entire country of Scotland, are calling for the drug war to come to an end.

2022

2023 Bern Switzerland announced intent to conduct a pilot of legal cocaine sales.

2023

\$360 Billion+

2021

total addressable market





Our Model

Incubate and Invest Across the Value Chain

Our strategy is to invest in and incubate companies across the safe supply ecosystem to create a tightly woven fabric of synergies that generate short-term revenues to Safe Supply while also maximizing value accretion as our investee companies grow

As more jurisdictions move to decriminalize and legalize different psychoactive compounds, new opportunities will emerge.



Production

As reform programs move forward, governments will need trusted sources of the different compounds to distribute to the programs.



Import/Export

Production of certain materials already occurs legally, such as the production of the coca plant in Peru. We will invest in companies importing / exporting such materials.



Science & Innovation

Schedule 1-3 compounds such as cannabis, psychedelics and others have been a source of many new medicines for approval and this trend will continue as other drugs are descheduled.



Education & Information

Governments are investing heavily in educating people and communities in how to safely prepare to safely rediscover this powerful compounds



Clinics and Distribution

The emerging market for psychoactive compounds will need new distribution pathways and clinical infrastructure to be delivered.



Therapeutic Applications

Many new applications in energy drinks, functional foods, pharmaceutical and nutraceutical are expected to emerge.



Testing & Analytics

Ensuring testing and analytical purity will be essential for new programs to operate effectively.

Our Team



Pioneers across the drug reform ecosystem.



Bill Panagiotakapoulos

Chairman, CEO







David Bhumgara

CFO







Setti Coscarella

VP, Corporate Development





Our Board & Advisors



Supported by some of the brightest minds in the world.

Board of Directors







Setti Coscarella



Frank Salvati



Najla Guthrie



Dr. Obaji James

Board of Advisors



Ronan Levy



Aaron Sonshine



Michael Astone



Tenzin Khangsar



Dr. Roger Ferreira



Ronnie Jaegermann



Our Advantage



Our team is made up of first movers in earlier drug reform investment opportunities, and we are a first mover in the third wave of drug reform.

First Mover in Third Wave of Decriminalization

Safe Supply is one of the first companies actively deploying capital into the third wave of drug reform, specifically on ending the fentanyl crisis and emerging opportunities for the coca plant.

Government Relationships

As we have been working as with governments and regulatory bodies around the world in the drug reform movement, we work closely with policy and decision-makers in government.

Extensive Capital Markets Experience

All members of the leadership team have executive level experience leading public companies and have collectively raised and deployed \$3.5B+ in capital and have created \$10B+ in shareholder value across their respective companies.

Access to Opportunities

Our team has been active in investing in drug reform for over a decade, giving us unparalleled access to investment opportunities and strategies.



Our Portfolio

Hearts, Minds, Capital & Synergies

The Safe Supply ecosystem brings together the people, know-how, capital and partnerships

Foundational Investments

CannaLabs: Licensed by Health Canada, that will be conducting cutting-edge research on MDMA, cocaine, DMT, ketamine and other psychoactive compounds that will be foundational to the development of the safe supply ecosystem. It can also conduct analytics and testing for any compounds manufactured in Canada or imported that will support safe supply programs in Canada.

Safe Supply Licensing Co.: In the late-stage application process for a dealers' license pursuant to the CDSA to be able to import and test controlled substances to connect investee companies to a federal license for Schedule 1- 3 compounds.

More Investments Coming Soon

The leadership team has developed a proprietary pipeline of early-stage companies that have strong management teams and well-designed business strategies that will play a pivotal role in the burgeoning safe supply ecosystem. The company expects to execute on many of these opportunities over the next 6 – 12 months.







Safe Supply in British Columbia

The Canadian Province of British Columbia has become the most progressive jurisdiction in the world bringing an end to the drug war.

Initiatives include:

- Investing over \$1B in 2023 to combat the toxic drug supply
- Drug-checking services

- Overdose prevention and supervised consumption sites
- Prescribed safer supply

This is creating a



per year opportunity in British Columbia for safely supplied cocaine.



Renewed Interest in the Coca Plant

The coca plant (excluding cocaine) is experiencing renewed interest from both the nutraceutical and pharmaceutical industries.

Therapeutic applications of coca leaf include:

- Energy
- Digestion
- High in protein and vitamins

- Weight loss
- Carbohydrate metabolism
- Pain management

Addressable markets (per year):

\$50B

energy drinks

\$275B

functional foods

\$382B

pharmaceuticals



Responding to the Fentanyl Overdose Crisis

- 1.22M Americans have died from the opioid epidemic in the last decade.
- 74K Americans died from fentanyl-related overdoses in 2022
- While fentanyl test strips were once considered "drug paraphernalia" and illegal in the US, they are now legal in a majority of US states

Globally, the fentanyl test strip market is expected to grow to

per year by 2030 and





Legalization & Rescheduling in Australia, Colorado, Oregon and Europe

- In 2023, Bern, Switzerland announced an intention to conduct a pilot program to legalize the sale of cocaine.
- In 2023, the State of Oregon created the first legal market for psilocybin services, with an estimated market size of \$1B per year.
- In 2023, Australia rescheduled psilocybin and MDMA permitting their use for the treatment of certain mental health conditions, with an estimated market size of \$2B per year.
- In 2025, the State of Colorado will create the first legal market for plant-based psychedelics.
- The FDA is expected to approve the use of MDMA-assisted therapy for the treatment of PTSD in 2024.

States including New York, California, Hawaii, Connecticut and others are exploring creating legal markets as well, creating a global




per year market.



B B C 👤 Sign in

In the News

Change is Happening All around the world.



SWI swissinfo.ch

Swiss perspectives in 10 languages





would not otherwise be available.

We are democratizing access to investing in ending the war on drugs.



Investment Highlights

Safe Supply presents the smartest way to invest in the emerging safe supply ecosystem and the third wave of drug reform.

Portfolio of Diversified Assets

Diversification inherently reduces investment risk. By holding a varied range of assets within the safe supply sector, investors are better positioned against potential downturns in any single asset, enhancing stability and consistent growth potential.

Early Entry into a Burgeoning Sector

Investors will benefit from the company's first-mover advantage, capitalizing on opportunities before they become mainstream and potentially generating higher returns.

World-Class Team

Our seasoned team brings expertise, experience, and a proven track record. Investors can be assured that the company's strategies and operations are being steered by industry veterans.

Unique Model with High-Velocity Deployment into Investments

A quick turnaround time in investment deployment maximizes the time assets are working to generate returns. This approach ensures investors' capital is always optimally employed, potentially leading to higher yields in shorter durations.



Investment Highlights

Safe Supply presents the smartest way to invest in the emerging safe supply ecosystem and the third wave of drug reform.

Strategic Positioning Post Decriminalization

Regulatory changes, such as decriminalization, often unlock vast market potentials. Investing in a company poised to capitalize on these changes allows investors to ride the upward momentum, tapping into newly accessible revenue streams.

'Strategic' Financial Model

With the majority of capital being diligently funneled into high-potential deals, investors can expect enhanced returns. The model's efficiency ensures that capital is not lying dormant but is actively seeking and capitalizing on profitable ventures.

Streaming Model Ensuring Diversified Exposure

The streaming model guarantees that investments are spread across the value chain of the safe supply sector. This ensures that investors are not overexposed to any single segment, providing both safety and multiple growth avenues.

Commitment to Innovation and Evolution

The safe supply sector, especially post-decriminalization, is ripe for innovation.

A company committed to staying ahead of the curve ensures that investors are always part of the next big breakthrough, leading to sustained growth and profitability.



Contact

Chief Executive Officer bill@safesupplystreaming.com